Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company, which focuses on the research, development and commercialization of small molecule drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lead product, migalastat HCl, a small molecule, is indicated for the treatment of Fabry disease. The other products in the pipeline include ATB200/AT2221 for the treatment of Pompe disease, Fabry disease, and other lysosomal storage disorders; migalastat for other conditions; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Philadelphia, Philadelphia, the US.
Headquarters
United States of America
Address
3675 Market Street, Philadelphia, Pennsylvania, 19104
Website
www.amicusrx.com
Telephone
1 215 9217600
No of Employees
496
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FOLD (NASD)
Revenue (2022)
$305.5M
17.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
9.5%
(2022 vs 2021)
Market Cap*
$3.5B
Net Profit Margin (2022)
XYZ
22.8%
(2022 vs 2021)
* As of and is in US$
Amicus Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Migalastat HCl - Fabry disease | Amicus Assist |
| Pipeline | Galafold |
| ATB200/AT2221 | CHART |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Amicus Therapeutics Inc | BioMarin Pharmaceutical Inc | RegeneRx Biopharmaceuticals Inc | Astellas Gene Therapies | Dewpoint Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Philadelphia | Novato | Rockville | San Francisco | Boston |
| State/Province | Pennsylvania | California | Maryland | California | Massachusetts |
| No. of Employees | 496 | 3,045 | 3 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John F. Crowley | Chairman; Chief Executive Officer | Executive Board | 2010 | 55 |
| Bradley L. Campbell | Director; Chief Operating Officer; President | Executive Board | 2015 | 46 |
| Daphne Quimi | Chief Financial Officer | Senior Management | 2019 | 56 |
| Ellen S. Rosenberg | Chief Legal Officer | Senior Management | - | 59 |
| David Clark | Chief People Officer | Senior Management | 2018 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward